Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat - Willis, Brian A; Andersen, Scott W; Ayan-Oshodi, Mosun; James, Douglas E; Liffick, Emily; Hillgren, Kathleen; Guo, Yingying; Monk, Scott A (Journal of clinical pharmacology, 2020)
Keywords: Adult; Amyloid Precursor Protein Secretases - antagonists & inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2 - antagonists & inhibitors; ATP Binding Cassette Transporter, Subfamily G, Member 2 - genetics; ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism; Cross-Over Studies; Drug Interactions; Drug-Related Side Effects and Adverse Reactions - genetics; Drug-Related Side Effects and Adverse Reactions - metabolism; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - pharmacology; European Continental Ancestry Group; Female; Genotype; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage; Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacokinetics; Imidazoles - pharmacokinetics; Imidazoles - pharmacology; Male; Middle Aged; Neoplasm Proteins - antagonists & inhibitors; Neoplasm Proteins - genetics; Neoplasm Proteins - metabolism; Polymorphism, Genetic; Rosuvastatin Calcium - administration & dosage; Rosuvastatin Calcium - adverse effects; Rosuvastatin Calcium - pharmacokinetics; Spiro Compounds - pharmacokinetics; Spiro Compounds - pharmacology; Young Adult; BCRP; lanabecestat; Alzheimer's disease; rosuvastatin; β-site amyloid precursor protein-cleaving enzyme 1